Clinical Trials Browser

Phase 1 × INDUSTRY × etaracizumab × Clear all

NCT00111696 2012-03-14

Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

Phase 1 Completed

Melanoma

NCT00263783 2009-01-29

Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors

Phase 1 Completed

Neoplasms